HBM Healthcare Investments Reports Strong Start to Financial Year 2024/2025

HBM Healthcare Investments announced a quarterly profit of CHF 26 million for the first three months of the 2024/2025 financial year. The net asset value (NAV) per share increased by 1.6 percent, while the share price rose by 5.9 percent.

The private portfolio companies were the primary value drivers, contributing CHF 53 million to the result. Public companies had a negative impact of CHF –14 million, with funds contributing CHF –4 million negatively.

Among public companies, notable performers were Insmed and Merus, each adding CHF 10 million, while Y-mAbs Therapeutics and Biohaven were among the laggards. Private company highlights included Johnson & Johnson’s acquisition of Yellow Jersey Therapeutics, adding CHF 59 million, and Swixx BioPharma’s market expansion.

The macroeconomic environment remains challenging. HBM Healthcare Investments will continue cautious operations while maintaining a diversified and well-positioned portfolio.